Detalles de la búsqueda
1.
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671).
Ann Oncol
; 2024 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38857846
2.
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.
World J Urol
; 38(1): 143-150, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30993426
3.
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials.
ESMO Open
; 9(3): 102941, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38452437
4.
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).
ESMO Open
; 6(2): 100054, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33601296
5.
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
ESMO Open
; 6(2): 100099, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33819752
6.
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].
ESMO Open
; 6(2): 100097, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33926709
Resultados
1 -
6
de 6
1
Próxima >
>>